Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SSX2IP (Afadin- and alpha-actinin-binding protein) is an adaptor protein implicated in the organization of adherens junctions and centrosome maturation within the cell. It binds to afadin and alpha-actinin, connecting the nectin-afadin system with the E-cadherin–catenin complex, thereby helping to organize the cytoskeleton and maintain cell-to-cell junction integrity. SSX2IP also interacts with WDR8, playing essential roles in centrosome maturation, spindle dynamics, and ciliogenesis, all functions relevant to normal cell division, cell migration, and tissue organization. Its association with cancer-testis antigens (such as SSX2) suggests possible cancer relevance, particularly in synovial sarcoma and leukemia. Although not yet an established therapeutic target, its molecular and functional roles position it as a candidate for further investigation in cell cycle control and malignancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Afadin- and alpha-actinin-binding protein (SSX2IP).